Forma wins $20M payout in Eisai pact

Eisai will tap into Forma Therapeutics' compound library and cell-based screening platforms under a discovery pact that will pay Forma $20 million in an upfront and committed funding over a three-year period. "Forma's unique drug discovery capabilities will enable Eisai to access diversified chemistry and drug discovery technologies to identify novel drug candidates for otherwise difficult targets," said Kentaro Yoshimatsu, CSO for Eisai Product Creation Systems. Eisai release

Suggested Articles

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.

AbbVie and Roche alum Janet Hammond, M.D., Ph.D., Sc.M., F.C.P. has nabbed the chief development officer role at infectious disease biotech Atea.